Who are Tenecteplase or Alteplase's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): rtPA, reteplase 10+10 U, alteplase dwell arm, Reteplase 10 U, TNKase, low-dose tenecteplase intravenous thrombolysis.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tenecteplase-or-alteplase.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Tenecteplase or Alteplase — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tenecteplase or Alteplase (Tenecteplase or Alteplase) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tissue plasminogen activator (tPA); fibrinolytic agent. Area: Cardiovascular.

marketed Tissue plasminogen activator (tPA); fibrinolytic agent Plasminogen; fibrin Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Tenecteplase or Alteplase (Tenecteplase or Alteplase) — Insel Gruppe AG, University Hospital Bern. Tenecteplase and alteplase are tissue plasminogen activators (tPA) that convert plasminogen to plasmin, which breaks down fibrin clots.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tenecteplase or Alteplase TARGET	Tenecteplase or Alteplase	Insel Gruppe AG, University Hospital Bern	marketed	Tissue plasminogen activator (tPA); fibrinolytic agent	Plasminogen; fibrin
rtPA	rtPA	Hui-Sheng Chen	marketed	Fibrinolytic agent; tissue plasminogen activator (tPA)	Plasminogen; fibrin
reteplase 10+10 U	reteplase 10+10 U	Sahlgrenska University Hospital	marketed	Fibrinolytic agent; tissue plasminogen activator (tPA) analog	Fibrin; plasminogen
alteplase dwell arm	alteplase dwell arm	University of Manitoba	marketed	Fibrinolytic agent / Tissue plasminogen activator (tPA)	Plasminogen
Reteplase 10 U	Reteplase 10 U	The University of Texas Health Science Center, Houston	marketed	Fibrinolytic agent; tissue plasminogen activator (tPA)	Fibrin; plasminogen
TNKase	TNKase	Cedars-Sinai Medical Center	marketed	Fibrinolytic agent; tissue plasminogen activator (tPA)	Fibrin; plasminogen
low-dose tenecteplase intravenous thrombolysis	low-dose tenecteplase intravenous thrombolysis	Southwest Hospital, China	marketed	Fibrinolytic agent / Tissue plasminogen activator (tPA)	Plasminogen / Fibrin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tissue plasminogen activator (tPA); fibrinolytic agent class)

Insel Gruppe AG, University Hospital Bern · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tenecteplase or Alteplase — Competitive Intelligence Brief. https://druglandscape.com/ci/tenecteplase-or-alteplase. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab